Savior LLC Acquires Shares of 1,413 Johnson & Johnson (NYSE:JNJ)

Savior LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,413 shares of the company’s stock, valued at approximately $206,000.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Arjuna Capital raised its position in shares of Johnson & Johnson by 20.1% during the 2nd quarter. Arjuna Capital now owns 23,969 shares of the company’s stock valued at $3,338,000 after buying an additional 4,017 shares during the period. Susquehanna Fundamental Investments LLC raised its position in shares of Johnson & Johnson by 604.1% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 323,175 shares of the company’s stock valued at $45,012,000 after buying an additional 277,275 shares during the period. United Services Automobile Association raised its position in shares of Johnson & Johnson by 13.7% during the 2nd quarter. United Services Automobile Association now owns 2,173,464 shares of the company’s stock valued at $302,720,000 after buying an additional 261,936 shares during the period. Eaton Vance Management raised its position in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Eaton Vance Management now owns 5,956,603 shares of the company’s stock valued at $828,806,000 after buying an additional 83,618 shares during the period. Finally, Phocas Financial Corp. raised its position in shares of Johnson & Johnson by 999,928.6% during the 2nd quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $174,342,000 after buying an additional 125,161,066 shares during the period. 67.36% of the stock is currently owned by institutional investors.

In related news, Director Hubert Joly bought 5,000 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average cost of $141.28 per share, with a total value of $706,400.00. Following the purchase, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $706,400. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 2,017 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $141.07, for a total value of $284,538.19. Following the transaction, the executive vice president now directly owns 51,736 shares of the company’s stock, valued at $7,298,397.52. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

A number of analysts have issued reports on the company. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price on the stock in a research report on Wednesday, December 18th. Wells Fargo & Co raised their price target on Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a research report on Thursday, January 9th. Morgan Stanley raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $145.00 to $170.00 in a research note on Tuesday, December 17th. Barclays raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $140.00 to $173.00 in a research note on Thursday, December 19th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $168.00 price objective on shares of Johnson & Johnson in a report on Thursday. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus price target of $161.33.

Johnson & Johnson stock opened at $148.53 on Friday. The firm has a market cap of $390.18 billion, a PE ratio of 21.91, a price-to-earnings-growth ratio of 2.39 and a beta of 0.71. Johnson & Johnson has a 52-week low of $125.00 and a 52-week high of $150.17. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. The company’s 50 day moving average is $144.84 and its two-hundred day moving average is $135.12.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $1.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.01. The business had revenue of $20.75 billion during the quarter, compared to the consensus estimate of $20.83 billion. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.30%. The company’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.97 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 9.06 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.56%. The ex-dividend date of this dividend is Monday, February 24th. Johnson & Johnson’s payout ratio is currently 43.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What is meant by a buy rating?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.